The contemporary role of chemotherapy for advanced testis cancer

A systematic review of the literature

Fabio Calabrò, Peter Albers, Carsten Bokemeyer, Chris Martin, Lawrence Einhorn, Alan Horwich, Susanne Krege, Hans Joachim Schmoll, Cora N. Sternberg, Gedske Daugaard

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Context: Germ cell tumours (GCTs) of the testis are the most common cancer in young men; they are also one of the most curable cancers. Standard treatment of metastatic GCTs has evolved on the basis of randomised trials and prognostic factors. Objective: This review summarises the evolving role of chemotherapy in the treatment of previously treated and untreated patients with metastatic GCTs and outlines the current standard treatment. Evidence acquisition: Randomised and nonrandomised trials of first-line, salvage, and palliative therapy were reviewed. Evidence synthesis: Three cycles of standard bleomycin, etoposide, and platinum (BEP) can be considered the gold-standard treatment in good-risk patients, and four cycles of the same combination can result in cure in approximately 80% of intermediate-risk and 50% of poor-risk patients. The routine use of high-dose chemotherapy in patients with intermediate- or poor-prognosis GCT has not improved treatment outcome, but the role of tumour marker decline during the first cycles may provide useful prognostic information. Prognostic variables in patients who experience treatment failure after cisplatin-based chemotherapy can be used to guide salvage strategies, and many new drugs or combinations have shown activity in this setting. Patients and physicians should be aware of the risk of short- and long-term toxicity of treatments, and guidelines for screening and prevention of this risk should be established. Conclusions: A risk-based strategy offers the best chance of cure, even in patients with refractory GCT.

Original languageEnglish
Pages (from-to)1212-1221
Number of pages10
JournalEuropean Urology
Volume61
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Testicular Neoplasms
Germ Cell and Embryonal Neoplasms
Drug Therapy
Therapeutics
Salvage Therapy
Bleomycin
Etoposide
Drug Combinations
Tumor Biomarkers
Platinum
Treatment Failure
Palliative Care
Gold
Cisplatin
Testis
Neoplasms
Guidelines
Physicians

Keywords

  • Chemotherapy
  • Conventional-dose chemotherapy
  • High-dose chemotherapy
  • Long-term toxicity
  • Metastatic germ cell tumours
  • Prognostic factors
  • Tumour markers

ASJC Scopus subject areas

  • Urology

Cite this

The contemporary role of chemotherapy for advanced testis cancer : A systematic review of the literature. / Calabrò, Fabio; Albers, Peter; Bokemeyer, Carsten; Martin, Chris; Einhorn, Lawrence; Horwich, Alan; Krege, Susanne; Schmoll, Hans Joachim; Sternberg, Cora N.; Daugaard, Gedske.

In: European Urology, Vol. 61, No. 6, 06.2012, p. 1212-1221.

Research output: Contribution to journalArticle

Calabrò, F, Albers, P, Bokemeyer, C, Martin, C, Einhorn, L, Horwich, A, Krege, S, Schmoll, HJ, Sternberg, CN & Daugaard, G 2012, 'The contemporary role of chemotherapy for advanced testis cancer: A systematic review of the literature', European Urology, vol. 61, no. 6, pp. 1212-1221. https://doi.org/10.1016/j.eururo.2012.03.038
Calabrò, Fabio ; Albers, Peter ; Bokemeyer, Carsten ; Martin, Chris ; Einhorn, Lawrence ; Horwich, Alan ; Krege, Susanne ; Schmoll, Hans Joachim ; Sternberg, Cora N. ; Daugaard, Gedske. / The contemporary role of chemotherapy for advanced testis cancer : A systematic review of the literature. In: European Urology. 2012 ; Vol. 61, No. 6. pp. 1212-1221.
@article{31c6349e8ab6426b9411a01fcf0e25b6,
title = "The contemporary role of chemotherapy for advanced testis cancer: A systematic review of the literature",
abstract = "Context: Germ cell tumours (GCTs) of the testis are the most common cancer in young men; they are also one of the most curable cancers. Standard treatment of metastatic GCTs has evolved on the basis of randomised trials and prognostic factors. Objective: This review summarises the evolving role of chemotherapy in the treatment of previously treated and untreated patients with metastatic GCTs and outlines the current standard treatment. Evidence acquisition: Randomised and nonrandomised trials of first-line, salvage, and palliative therapy were reviewed. Evidence synthesis: Three cycles of standard bleomycin, etoposide, and platinum (BEP) can be considered the gold-standard treatment in good-risk patients, and four cycles of the same combination can result in cure in approximately 80{\%} of intermediate-risk and 50{\%} of poor-risk patients. The routine use of high-dose chemotherapy in patients with intermediate- or poor-prognosis GCT has not improved treatment outcome, but the role of tumour marker decline during the first cycles may provide useful prognostic information. Prognostic variables in patients who experience treatment failure after cisplatin-based chemotherapy can be used to guide salvage strategies, and many new drugs or combinations have shown activity in this setting. Patients and physicians should be aware of the risk of short- and long-term toxicity of treatments, and guidelines for screening and prevention of this risk should be established. Conclusions: A risk-based strategy offers the best chance of cure, even in patients with refractory GCT.",
keywords = "Chemotherapy, Conventional-dose chemotherapy, High-dose chemotherapy, Long-term toxicity, Metastatic germ cell tumours, Prognostic factors, Tumour markers",
author = "Fabio Calabr{\`o} and Peter Albers and Carsten Bokemeyer and Chris Martin and Lawrence Einhorn and Alan Horwich and Susanne Krege and Schmoll, {Hans Joachim} and Sternberg, {Cora N.} and Gedske Daugaard",
year = "2012",
month = "6",
doi = "10.1016/j.eururo.2012.03.038",
language = "English",
volume = "61",
pages = "1212--1221",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - The contemporary role of chemotherapy for advanced testis cancer

T2 - A systematic review of the literature

AU - Calabrò, Fabio

AU - Albers, Peter

AU - Bokemeyer, Carsten

AU - Martin, Chris

AU - Einhorn, Lawrence

AU - Horwich, Alan

AU - Krege, Susanne

AU - Schmoll, Hans Joachim

AU - Sternberg, Cora N.

AU - Daugaard, Gedske

PY - 2012/6

Y1 - 2012/6

N2 - Context: Germ cell tumours (GCTs) of the testis are the most common cancer in young men; they are also one of the most curable cancers. Standard treatment of metastatic GCTs has evolved on the basis of randomised trials and prognostic factors. Objective: This review summarises the evolving role of chemotherapy in the treatment of previously treated and untreated patients with metastatic GCTs and outlines the current standard treatment. Evidence acquisition: Randomised and nonrandomised trials of first-line, salvage, and palliative therapy were reviewed. Evidence synthesis: Three cycles of standard bleomycin, etoposide, and platinum (BEP) can be considered the gold-standard treatment in good-risk patients, and four cycles of the same combination can result in cure in approximately 80% of intermediate-risk and 50% of poor-risk patients. The routine use of high-dose chemotherapy in patients with intermediate- or poor-prognosis GCT has not improved treatment outcome, but the role of tumour marker decline during the first cycles may provide useful prognostic information. Prognostic variables in patients who experience treatment failure after cisplatin-based chemotherapy can be used to guide salvage strategies, and many new drugs or combinations have shown activity in this setting. Patients and physicians should be aware of the risk of short- and long-term toxicity of treatments, and guidelines for screening and prevention of this risk should be established. Conclusions: A risk-based strategy offers the best chance of cure, even in patients with refractory GCT.

AB - Context: Germ cell tumours (GCTs) of the testis are the most common cancer in young men; they are also one of the most curable cancers. Standard treatment of metastatic GCTs has evolved on the basis of randomised trials and prognostic factors. Objective: This review summarises the evolving role of chemotherapy in the treatment of previously treated and untreated patients with metastatic GCTs and outlines the current standard treatment. Evidence acquisition: Randomised and nonrandomised trials of first-line, salvage, and palliative therapy were reviewed. Evidence synthesis: Three cycles of standard bleomycin, etoposide, and platinum (BEP) can be considered the gold-standard treatment in good-risk patients, and four cycles of the same combination can result in cure in approximately 80% of intermediate-risk and 50% of poor-risk patients. The routine use of high-dose chemotherapy in patients with intermediate- or poor-prognosis GCT has not improved treatment outcome, but the role of tumour marker decline during the first cycles may provide useful prognostic information. Prognostic variables in patients who experience treatment failure after cisplatin-based chemotherapy can be used to guide salvage strategies, and many new drugs or combinations have shown activity in this setting. Patients and physicians should be aware of the risk of short- and long-term toxicity of treatments, and guidelines for screening and prevention of this risk should be established. Conclusions: A risk-based strategy offers the best chance of cure, even in patients with refractory GCT.

KW - Chemotherapy

KW - Conventional-dose chemotherapy

KW - High-dose chemotherapy

KW - Long-term toxicity

KW - Metastatic germ cell tumours

KW - Prognostic factors

KW - Tumour markers

UR - http://www.scopus.com/inward/record.url?scp=84860309577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860309577&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2012.03.038

DO - 10.1016/j.eururo.2012.03.038

M3 - Article

VL - 61

SP - 1212

EP - 1221

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 6

ER -